In the United States has allowed gene therapy to treat rare forms of vision loss

© Fotolia / Magaz person. Archival photoIn the United States has allowed gene therapy to treat rare forms of vision loss© Fotolia / Maxsim

Management on sanitary inspection behind quality of foodstuff and medicines (Food and Drug Administration, FDA) approved an innovative gene therapy for the treatment of patients with a rare form of hereditary loss of vision, reported on the Agency’s website.

According to the statement, approval of therapy called Luxturna developed by company Spark Therapeutics.

«The FDA today approved Luxturna, a new gene therapy to treat children and adult patients with hereditary form of vision loss that can lead to blindness. Luxturna is the first gene therapy approved in the United States, which is aimed at (treatment — ed.), diseases caused by mutations in a particular gene,» — said in the message.

«Today’s approval marks another achievement in the field of gene therapy, as in therapy and increased use of gene therapy beyond the treatment of cancer… this is the key point reinforces the potential of this revolutionary approach in the treatment of a wide range of complex diseases», — said the representative of management of the Scott Gottlieb.

Source